BRISTOL — Deirdre M. Daly, United States Attorney for the District of Connecticut, and Joel P. Garland, Special Agent in Charge of IRS Criminal Investigation in New England, announced that Robin Reid, 54, of Bristol, pleaded guilty to preparing false federal income tax returns.
According to court documents and statements made in court, Reid operated a tax return preparation practice.
From at least 2005 and continuing until 2015, Reid falsified information on numerous returns that she prepared for clients by inflating deductions for medical and dental expenses, charitable contributions, employee-related expenses, and other expenses.
Reid often created fictitious Schedule C forms in order to fabricate deductible business expenses, and fictitious Schedule E forms to inflate expenses relating to rental properties.
By routinely overstating deductions, Reid reduced taxable income on the respective returns, and caused a tax loss of $1,126,011 to the government.
Reid pleaded guilty to one count of aiding and assisting the filing of a false tax return, an offense that carries a maximum term of imprisonment of three years, a fine of up to approximately $2.2 million, and restitution.
Reid is scheduled for sentencing on December 21, 2017.
Reid’s clients are required to resolve their own tax liability with the Internal Revenue Service.
The Roundup currently has over 5,700 subscriptions and a local social media following of over 95,000 readers across multiple social media sites, apps, pages, and groups.
The Roundup is also a proud member of WordPress. This affiliation offers readers more news from FOX 61 and CBS Connecticut on The Roundup.
Recent Posts From Roundup Partner: CBS Connecticut
Two U.S. athletes have been placed on probation for 12 months for their political protests last week at the Pan Am Games.
CBS Sports HQ’s second annual live Fantasy Football Telethon will include expert advice from NFL experts, along with Q&As with former players.
A chemical found in the cannabis plant has demonstrated “significant therapy potential” in treatment of pancreatic cancer, according to researchers from Harvard University’s Dana-Farber Cancer Institute.